Navigation Links
China Cord Blood Corporation Announces Completion of Warrant Exchange
Date:12/13/2010

HONG KONG, Dec. 13, 2010 /PRNewswire-Asia-FirstCall/  - China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company"), the first and largest cord blood banking operator in China, today announced the completion of its previously announced warrant exchange offer, which allowed warrant holders to receive one ordinary share for every eight warrants outstanding.  The Company issued 1,627,518 ordinary shares, equivalent to 2.2% of shares outstanding as of December 10, 2010, in exchange for 13,020,236 warrants.  Investors participating in the warrant exchange offer are subject to a 45-day lock up period with regard to ordinary shares acquired in the exchange offer.

Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation commented, "We believe shareholders will appreciate our simplified capital structure. With no further dilution, shareholders will fully enjoy the benefits of our operational accomplishments and robust growth, even on a per share basis.  With all the stakeholders' interests now fully aligned, we will continue to expand our dominance within the China market, as well as the Asia Pacific region, to better capitalize on emerging opportunities."

Immediately after giving effect to the warrant exchange, China Cord Blood Corporation will have 75,406,868 ordinary shares issued and outstanding, and any remaining warrants outstanding that are not exercised will expire at 5:00 p.m. U.S. Eastern Time on the date of this press release.

About China Cord Blood CorporationChina Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses.  Under the current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.  For more information, please visit our website at http://www.chinacordbloodcorp.com.  

Important Additional InformationThis press release and the description contained herein are for informational purposes only and are not an offer to purchase or a solicitation of an offer to sell securities of the Company.  

For more information, please contact:China Cord Blood CorporationMs. Joeling LawTel: (+852) 3605-8180Email: ir@chinacordbloodcorp.comICR, LLCIn New York: Ashley M. Ammon: 1-646-277-1227In Beijing: Wen Lei Zheng: +86-10-6583-7510
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. China Medicine Announces Strong Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China Biologic Products Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on ... that it will present at the 18 th ... 8, 2016 at 10:00 a.m. EST in New ... DelMar,s president and CEO, will provide an update on the ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/4/2016)... Strasbourg, France , to the US ... Strasbourg, France , to the US company Advanced Bioscience ... announce that it acted as an advisor to Transgene on ... Strasbourg, France , to the US company Advanced Bioscience ... Transgene (Euronext: TNG), a member of Institut Mérieux, is ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
Breaking Biology Technology:
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 /PRNewswire/ ... sensor-based diagnostic products, today announced the closing of a $9 ... investors.  Proceeds from the financing will be used to accelerate ... device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has been ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
(Date:1/6/2016)... Jan. 6, 2016 Based on its ... & Sullivan recognizes MorphoTrak, LLC, a U.S. subsidiary ... Frost & Sullivan Company of the Year Award. ... technology, Morpho Wave™ , has consolidated the company,s ... biometrics market. Morpho Wave is a highly ...
Breaking Biology News(10 mins):